基于药物非临床安全性评价的毒性病理学同行评议流程及要求探讨

doi:10.19803/j.1672-8629.2020.11.09

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 790-793.
DOI: 10.19803/j.1672-8629.2020.11.09

基于药物非临床安全性评价的毒性病理学同行评议流程及要求探讨

李建华, 赵良友, 刘树民

黑龙江中医药大学药物安全性评价中心,哈尔滨黑龙江 150040

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
通讯作者: ^*刘树民,男,教授,中药药效物质基础与中药药性理论。E-mail:Keji-Liu@163.com
作者简介:李建华,男,硕士,毒性病理学。
基金资助:
国家重点基础研究发展计划（2013CB531804）：基于利水功效的中药药性理论研究

Processes and Requirements of Peer Review of Toxicological Pathology Based on GLP

LI Jian Hua, ZHAO Liang You, LIU Shu Min

Drug Safety Evaluation Center of Heilongjiang University of Traditional Chinese Medicine, Harbin Heilongjiang 150040, China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的探讨毒性病理学同行评议的流程和要求,完善其内容以使同行评议更好地实施。方法以相关中英文关键词在中国知网、万方数据、Pubmed等数据库中进行检索,检索时间为1998年12月31日至2018年12月31日,对毒性病理学同行评议流程和要求的内容进行归纳总结与探讨。结果与结论 共检索相关文献12 657条,筛选其中文献22篇,通过文献查阅得出国内外毒性病理学同行评议的流程和要求的诸项条例基本相同,但我国规范的毒性病理学同行评议只包含条例而没有条例解释;国外毒性病理学同行评议已经施行,在实施过程中也对很多条例内容加以完善。

关键词: 毒性病理学, 同行评议流程, 同行评议要求, 病理学家

Abstract: Objective To explore the processes and requirements of peer review of toxicological pathology in order to ensure more effective peer review in China. Methods With "toxicological pathology" "peer review process" "peer review requirements" and "pathologist" as key words, the China HowNet、Wanfang、CNKI and Pubmed databases from December 1998 to December 2018 were searched to retrieve articles related to peer review processes and requirements of toxicological pathology before the content of these articles was analyzed and summarized. Results and Conclusion A total of 12,657 pieces of related literature were retrieved and 22 of them were screened out. Through literature review, it was concluded that the processes and requirements of peer review in the field of toxicological pathology were generally similar between China and other countries. However, in China's codes regarding peer review of toxicological pathology, only regulations are available, without any interpretations of these regulations. Peer review of toxicological pathology has been implemented abroad, and many regulations have been updated.

Key words: toxicological pathology, peer review process, peer review requirements, pathologists

中图分类号:

R994.1

李建华, 赵良友, 刘树民. 基于药物非临床安全性评价的毒性病理学同行评议流程及要求探讨[J]. 中国药物警戒, 2020, 17(11): 790-793.

LI Jian Hua, ZHAO Liang You, LIU Shu Min. Processes and Requirements of Peer Review of Toxicological Pathology Based on GLP[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 790-793.

参考文献

[1] Liu L,Li B.Non clinical safety of vaccines[J].Chinese Journal of New Drugs(中国新药杂志),2018,27(21):2472-2481.
[2] Yin JY,Wang HM,Qu WS, et al.Peer review of toxicity pathology based on the new "quality management standard for non clinical research of drugs"[J].Journal of International Pharmaceutical Research(国际药学研究杂志),2017,44(12):1085-1088.
[3] Boorman GA, Haseman JK, Waters MD, et al.Quality Review Procedures Necessary for Rodent PathologyDatabases and Toxico-genomic Studies:The National Toxicology Program Experience[J]. Toxicol Pathol,2002,30(1):88-92.
[4] Mann PC and Hardisty JH.Pathology working groups[J].Toxicol Pathol, 2014,42(1): 283-284.
[5] Wang JN,Cao C.Discussion on standardization of pathology department in GLP institution[J].Drug Evaluation Research(药物评价研究),2011,34(4):241-243.
[6] Standardization Administration of China.GB/T 22278-2008Principles of good laboratory practice(GB/T 22278-2008良好实验室规范原则)[M].Beijing: Standards Press of China,2008:8.
[7] Melnick R,Lucier G,Wolfe M,et al.Summary of the National Toxicology Program′s report of the endocrine disruptors low-dose peer review[J]. Environ Health Perspect,2002,110(4):427-431.
[8] Certification and Accreditation Administration of the Pe. RB/T193-2015 Guidelines for the application of good laboratory practice in peer review of histopathology (RB/T193-2015良好实验室规范在组织病理学同行评议中的应用指南)[M].Beijing: Standards Press of China,2016:4.
[9] Liang AH,Han JY,Chen SL,et al.Quality and safety considerations of classical Chinese medicine prescriptions[J].China Food Drug Admi-nistration(中国食品药品监管),2018(6):4-10.
[10] Ren SL,Peng L,Cheng SW,et al.Efficacy and safety of fluorouracil combined with paracetamol in the treatment of knee osteoarthritis[J]. China Pharmacy(中国药房),2019,30(2):249-252.
[11] Zhang CL,Wang XC,Wang H,et al.Clinical observation of febuxostat in the treatment of type 2 diabetic nephropathy with hyperuricemia[J]. China Pharmacy(中国药房),2018,29(4):501-505.
[12] Yoshitomi.Peer review in toxicologic histopathology: its necessity, type and procedure[J].Toxicol Sci,1998, 23(Supplement 1):1-9.
[13] McLennan, Ludvik, Chambers, Frydenberg.Work after prostate cancer: a systematic review[J]. Cancer Surviv, 2019,13(2):282-291.
[14] Lv JJ,Qu Z,Huo GT.Interpretation of guidelines for GLP requi-rements of OECD histopathology peer review[J].Chinese Pharma-ceutical Affairs(中国药事),2016,30(10): 968-976.
[15] Fikes JD, Patrick DJ, Francke S, et al.Scientific and Regulatory Policy Committee Review: Review of the Organisation for Economic Co-operation and Development (OECD) Guidance on the GLP Requirements for Peer Review of Histopathology[J]. Toxicol Pathol, 2015,43(7):907-914.
[16] Gupta,Rispin,Stitzel,Coecke,Harbell. Ensuring quality of in vitro alternative test methods: issues and answers[J].Regul Toxicol Pharmacol, 2005, 43(3):219-24.
[17] Ward,Hardisty,Hailey,Streett.Peer review in toxicologic pathology[J]. Toxicol Pathol.1995, 23(2):226-34.
[18] Mann PC.Pathology peer review from the perspective of an external peer review pathologist[J].Toxicol Pathol,1996,24(5):650-653.
[19] Lv JJ,Huo GT,Lin Z,et al.Application of whole section image in histopathology peer review and pathology working group[J].Chinese Pharmaceutical Affairs(中国药事),2016,30(10):982-987.
[20] Crissman JW, Goodman DG, Hildebrandt PK, et al.Best practices guideline: toxicologic histopathology[J].Toxicol Pathol,2004, 32(1):126-131.
[21] Dong YS.Standardization construction and practice of toxicity pathology platform for drug safety evaluation[D].Academy of Military Medical Sciences,2012.
[22] Eighmy JJ.Study Pathologist Perspective of Pathology Peer Review[J]. Toxicol Pathol, 1996, 24(5): 647-649.

基于药物非临床安全性评价的毒性病理学同行评议流程及要求探讨

Processes and Requirements of Peer Review of Toxicological Pathology Based on GLP

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	孙绮悦, 赵荣华, 包蕾, 郭姗姗, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 基于多动物模型药效评价体系研究羚羊感冒口服液儿童用药剂量[J]. 中国药物警戒, 2024, 21(2): 121-126.
[2]	孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131.
[3]	赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136.
[4]	包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140.
[5]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[6]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[7]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[8]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[9]	王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194.
[10]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[11]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[12]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[13]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[14]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[15]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.